Lpath Receives DoD Grant to Study Potential Traumatic Brain Injury Pain Treatment
California-based biotechnology firm Lpath has secured a two-year, $1.45 million grant from the Defense Department to examine the use of a monoclonal antibody drug as a potential treatment for neuropathic pain associated with traumatic brain injury. Lpath said Monday it will conduct preclinical studies to assess the effect of the company’s experimental drug Lpathomab on pain that follows neurotrauma as the company seeks to validate the findings […] More